ALT5 Sigma (NASDAQ:ALTS) Trading Down 6.9% – Here’s Why

ALT5 Sigma Corporation (NASDAQ:ALTS) shares dropped 6.9% on Tuesday . The stock traded as low as $1.21 and last traded at $1.22. Approximately 2,923,884 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 3,122,603 shares. The stock had previously closed at $1.31.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

ALT5 Sigma Stock Down 6.9%

The firm has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $2.70. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 0.01.

ALT5 Sigma (NASDAQ:ALTS) last released its quarterly earnings data on Monday, January 12th. The company reported $0.29 earnings per share (EPS) for the quarter. The business had revenue of $7.58 million for the quarter. ALT5 Sigma had a return on equity of 8.60% and a net margin of 133.06%.

Hedge Funds Weigh In On ALT5 Sigma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC bought a new stake in ALT5 Sigma in the third quarter valued at about $45,000. Captrust Financial Advisors boosted its holdings in ALT5 Sigma by 116.3% during the fourth quarter. Captrust Financial Advisors now owns 37,300 shares of the company’s stock valued at $41,000 after purchasing an additional 20,054 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in ALT5 Sigma during the third quarter valued at approximately $33,000. Crcm LP grew its stake in shares of ALT5 Sigma by 373.2% in the 4th quarter. Crcm LP now owns 10,941,280 shares of the company’s stock valued at $12,035,000 after purchasing an additional 8,629,103 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of ALT5 Sigma in the 4th quarter worth approximately $110,000. 6.27% of the stock is owned by institutional investors.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.